LYM
MCID: LYM017
MIFTS: 63

Lyme Disease (LYM)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lyme Disease

MalaCards integrated aliases for Lyme Disease:

Name: Lyme Disease 12 74 52 25 58 54 42 3 43 15 17 71 32
Lyme Borreliosis 12 52 25 58 15
Lyme Neuroborreliosis 12 54 43 71
Borrelia Burgdorferi Infection 25 3
Neuroborreliosis 12 71
Borreliosis 52 54
Infection Due to Borrelia Burgdorferi Sensu Lato 25
Infection by Borrelia Burgdorferi 25
Neurological Lyme Disease 12
B. Burgdorferi Infection 25
Bannworth's Syndrome 12
Borrelia Infections 71
Bannwarth Syndrome 12
Borreliosis, Lyme 25
Lym 74

Characteristics:

Orphanet epidemiological data:

58
lyme disease
Inheritance: Not applicable; Prevalence: >1/1000 (Europe),1-5/10000 (France); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11729
ICD9CM 34 088.81
NCIt 49 C45161
SNOMED-CT 67 23502006 48982009
ICD10 32 A69.2 A69.20
MESH via Orphanet 44 D008193
ICD10 via Orphanet 33 A69.2
UMLS via Orphanet 72 C0024198
Orphanet 58 ORPHA91546
UMLS 71 C0006035 C0024198 C0752235 more

Summaries for Lyme Disease

MedlinePlus : 42 What is Lyme disease? Lyme disease is a bacterial infection you get from the bite of an infected tick. At first, Lyme disease usually causes symptoms such as a rash, fever, headache, and fatigue. But if it is not treated early, the infection can spread to your joints, heart, and nervous system. Prompt treatment can help you recover quickly. What causes Lyme disease? Lyme disease is caused by bacteria. In the United States, this is usually a bacterium called Borrelia burgdorferi. It spreads to humans through the bite of an infected tick. The ticks that spread it are blacklegged ticks (or deer ticks). They are usually found in the Northeast Mid-Atlantic Upper Midwest Pacific coast, especially northern California These ticks can attach to any part your body. But they are often found in hard-to-see areas such as your groin, armpits, and scalp. Usually the tick must be attached to you for 36 to 48 hours or more to spread the bacterium to you. Who is at risk for Lyme disease? Anyone can get a tick bite. But people who spend lots of time outdoors in wooded, grassy areas are at a higher risk. This includes campers, hikers, and people who work in gardens and parks. Most tick bites happen in the summer months when ticks are most active and people spend more time outdoors. But you can get bitten in the warmer months of early fall, or even late winter if temperatures are unusually high. And if there is a mild winter, ticks may come out earlier than usual. What are the symptoms of Lyme disease? Early symptoms of Lyme disease start between 3 to 30 days after an infected tick bites you. The symptoms can include A red rash called erythema migrans (EM). Most people with Lyme disease get this rash. It gets bigger over several days and may feel warm. It is usually not painful or itchy. As it starts to get better, parts of it may fade. Sometimes this makes the rash look like a "bull's-eye." Fever Chills Headache Fatigue Muscle and joint aches Swollen lymph nodes If the infection is not treated, it can spread to your joints, heart, and nervous system. The symptoms may include Severe headaches and neck stiffness Additional EM rashes on other areas of your body Facial palsy, which is a weakness in your facial muscles. It can cause drooping on one or both sides of your face. Arthritis with severe joint pain and swelling, especially in your knees and other large joints Pain that comes and goes in your tendons, muscles, joints, and bones Heart palpitations, which are feelings that your heart is skipping a beat, fluttering, pounding, or beating too hard or too fast An irregular heart beat (Lyme carditis) Episodes of dizziness or shortness of breath Inflammation of the brain and spinal cord Nerve pain Shooting pains, numbness, or tingling in the hands or feet How is Lyme disease diagnosed? To make a diagnosis, your health care provider will consider Your symptoms How likely it is that you were exposed to infected blacklegged ticks The possibility that other illnesses may cause similar symptoms Results of any lab tests Most Lyme disease tests check for antibodies made by the body in response to infection. These antibodies can take several weeks to develop. If you are tested right away, it may not show that you have Lyme disease, even if you have it. So you may need to have another test later. What are the treatments for Lyme disease? Lyme disease is treated with antibiotics. The earlier you are treated, the better; it gives you the best chance of fully recovering quickly. After treatment, some patients may still have pain, fatigue, or difficulty thinking that lasts more than 6 months. This is called post-treatment Lyme disease syndrome (PTLDS). Researchers don't know why some people have PTLDS. There is no proven treatment for PTLDS; long-term antibiotics have not been shown to help. However, there are ways to help with the symptoms of PTLDS. If you have been treated for Lyme disease and still feel unwell, contact your health care provider about how to manage your symptoms. Most people do get better with time. But it can take several months before you feel all better. Can Lyme disease be prevented? To prevent Lyme disease, you should lower your risk of getting a tick bite: Avoid areas where ticks live, such as grassy, brushy, or wooded areas. If you are hiking, walk in the center of the trail to avoid brush and grass. Use an insect repellent with DEET Treat your clothing and gear with a repellant containing 0.5% permethrin Wear light-colored protective clothing, so you can easily see any ticks that get on you Wear a long-sleeve shirt and long pants. Also tuck your shirt into your pants and your pant legs into your socks. Check yourself, your children, and your pets daily for ticks. Carefully remove any ticks you find. Take a shower and wash and dry your clothes at high temperatures after being outdoors Centers for Disease Control and Prevention

MalaCards based summary : Lyme Disease, also known as lyme borreliosis, is related to intermediate uveitis and exanthem, and has symptoms including fatigue, fever and headache. An important gene associated with Lyme Disease is YBX3 (Y-Box Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Ceftriaxone and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and skin, and related phenotypes are arthritis and cranial nerve paralysis

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, has material basis in Borrelia burgdorferi, which is transmitted by blacklegged tick (Ixodes scapularis) or transmitted by western blacklegged tick (Ixodes pacificus). The infection has symptom fever, has symptom headache, has symptom fatigue, and has symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.

Genetics Home Reference : 25 Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. The bacteria are transferred to humans by tick bite, specifically by blacklegged ticks (commonly known as deer ticks). The condition is named for the location in which it was first described, the town of Lyme, Connecticut. Borrelia burgdorferi If not treated with antibiotics, Lyme disease follows three stages: early localized, early disseminated, and late disseminated infection. A small percentage of individuals have symptoms that persist months or years after treatment, which is called post-treatment Lyme disease syndrome. A characteristic feature of Lyme disease, and the key feature of early localized infection, is a slowly expanding red rash on the skin (called erythema migrans) at the site of the tick bite; the rash is often bull's-eye shaped. Flu-like symptoms and enlarged lymph nodes (lymphadenopathy) are also early signs of infection. Most people who are treated at this stage never develop further symptoms. The early disseminated stage of Lyme disease occurs as the bacteria is carried throughout the body in the bloodstream. This stage occurs a few weeks after the tick bite. Signs and symptoms can include additional rashes on other parts of the body, flu-like symptoms, and lymphadenopathy. Some affected individuals develop neurologic problems (referred to as neuroborreliosis), such as paralyzed muscles in the face (facial palsy); pain, numbness, or weakness in the hands or feet; difficulty concentrating; or memory problems. Rarely, the heart is affected (Lyme carditis), causing a sensation of fluttering or pounding in the chest (palpitations) or an irregular heartbeat. The late disseminated stage of Lyme disease can occur months to years after the tick bite. The most common feature of this stage, Lyme arthritis, is characterized by episodes of joint pain and swelling, usually affecting the knees. In rare cases, the late disseminated stage also involves neurological problems. Individuals with post-treatment Lyme disease syndrome report ongoing exhaustion (fatigue), muscle and joint achiness, headache, or difficulty concentrating even after treatment with antibiotics, when there is no evidence of the bacteria in the body. Very rarely, individuals have joint pain and swelling for months or years after successful antibiotic treatment. This complication is called antibiotic-refractory Lyme arthritis.

NIH Rare Diseases : 52 Lyme disease is the most common tickborne infectious disease in the United States. Early signs and symptoms of the condition include fever, chills, muscle pain, headache, and joint pain. As the condition progresses, affected people may experience heart problems, Bell's palsy , arthritis , abnormal muscle movement, speech problems and cognitive (thinking) abnormalities. Please visit the Center for Disease Control and Prevention's Web site for a more comprehensive list of symptoms. Lyme disease is caused by the bacterium Borrelia burgdorferi , which is transmitted to humans through the bite of infected blacklegged ticks. Certain features of the condition, including whether or not an affected person will develop medication-resistant chronic arthritis, is thought to be influenced by genetic factors (certain human leukocyte antigen genes ). Treatment generally includes antibiotics to address the bacterial infection and other medications (i.e. pain medications) to relieve symptoms.

CDC : 3 Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Wikipedia : 74 Lyme disease, also known as Lyme borreliosis, is an infectious disease caused by the Borrelia bacterium... more...

Related Diseases for Lyme Disease

Diseases related to Lyme Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1027)
# Related Disease Score Top Affiliating Genes
1 intermediate uveitis 32.9 TNF IL6 HLA-DRB1
2 exanthem 31.7 TNF IL6 CRP CD40LG
3 syphilis 31.5 IL17A HLA-DRB1 CRP CD40LG
4 neuritis 31.4 TNF IL6 IL1B
5 aseptic meningitis 31.2 TNF IL1B CD40LG
6 viral meningitis 31.2 IL6 CRP CD40LG
7 encephalitis 31.2 TNF IL6 IL1B CD40LG
8 uveitis 31.1 TNF IL6 IL17A HSPD1
9 bartonellosis 31.1 HSPD1 CRP CD40LG
10 mononeuropathy 31.1 TNF CRP CD40LG
11 acrodermatitis chronica atrophicans 31.1 CLDN11 CFHR2 CD40LG
12 meningoencephalitis 31.1 TNF IL6 CRP CD40LG
13 septic arthritis 31.1 TLR9 TLR2 CRP
14 erysipelas 31.1 TNF IL6 CRP CD40LG
15 myelitis 31.0 TNF IL6 IL17A CD40LG
16 fibromyalgia 31.0 TNF IL6 IL1B CRP
17 optic neuritis 31.0 TNF IL1B HLA-DRB1
18 orbital plasma cell granuloma 30.9 CRP CD40LG
19 transverse myelitis 30.9 TNF IL6 IL17A
20 proliferative glomerulonephritis 30.9 IL6 CFH C3
21 guillain-barre syndrome 30.9 TNF HLA-DRB1 CD40LG
22 synovitis 30.9 TNF IL6 IL1B CRP
23 chronic fatigue syndrome 30.9 TNF IL6 IL1B IL17A
24 haemophilus influenzae 30.8 TNF TLR2 CFH
25 myocarditis 30.8 TNF IL6 IL1B IL17A CD40LG
26 lymphoma, mucosa-associated lymphoid type 30.8 TLR2 TLR1 HSPD1 CD40LG
27 arthropathy 30.8 TNF IL6 IL1B CRP
28 neuroretinitis 30.8 CRP CD40LG
29 thrombotic thrombocytopenic purpura 30.7 HLA-DRB1 CFH CD40LG C3
30 esophagitis 30.7 TNF IL6 IL1B
31 neurosyphilis 30.7 TLR6 TLR2 TLR1 IL17A
32 posterior uveitis 30.7 TNF IL6 CFH
33 cellulitis 30.7 TNF IL6 CRP CD40LG
34 pericardial effusion 30.7 IL6 CRP CD40LG
35 juvenile rheumatoid arthritis 30.7 TNF IL6 IL1B HLA-DRB1 CRP
36 pyuria 30.7 IL6 CRP CD40LG C3
37 myositis 30.7 TNF IL6 IL1B IL17A HLA-DRB1
38 optic nerve disease 30.6 TNF IL6 IL17A CRP CD40LG
39 acute disseminated encephalomyelitis 30.6 IL1B HSPD1 HLA-DRB1 CD40LG
40 retinal vein occlusion 30.6 TNF IL6 CD40LG
41 eales disease 30.6 TNF IL6 IL1B
42 choroiditis 30.6 TNF CFH CD40LG
43 polyneuropathy 30.6 TNF IL6 IL1B CRP CD40LG
44 lepromatous leprosy 30.6 TNF TLR2 HSPD1
45 listeriosis 30.5 TNF TLR2 IL6
46 pericarditis 30.5 TNF IL6 IL1B CRP CD40LG
47 complex regional pain syndrome 30.5 TNF IL6 IL1B
48 rubella 30.5 TNF IL6 HLA-DRB1 CD40LG
49 amyloidosis 30.5 TNF IL6 CRP CD40LG
50 sleep disorder 30.5 TNF IL6 CRP

Graphical network of the top 20 diseases related to Lyme Disease:



Diseases related to Lyme Disease

Symptoms & Phenotypes for Lyme Disease

Human phenotypes related to Lyme Disease:

58 31 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
2 cranial nerve paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006824
3 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
4 meningitis 58 31 frequent (33%) Frequent (79-30%) HP:0001287
5 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
6 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
7 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
8 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
9 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
10 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
11 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
12 atrioventricular block 58 31 occasional (7.5%) Occasional (29-5%) HP:0001678
13 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
14 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
15 myalgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003326
16 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
17 amaurosis fugax 58 31 occasional (7.5%) Occasional (29-5%) HP:0100576
18 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
19 uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000554
20 insomnia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100785
21 skin nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0200036
22 dermal atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0004334
23 behavioral abnormality 58 Occasional (29-5%)
24 peripheral neuropathy 58 Occasional (29-5%)

Symptoms:

12
  • fatigue
  • fever
  • headache
  • skin rash called erythema migrans

UMLS symptoms related to Lyme Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Lyme Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 C3 C4A CFHR1 CLDN11 HSPD1 IL17A

MGI Mouse Phenotypes related to Lyme Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 C3 CD40LG CFH IL17A IL1B IL6
2 immune system MP:0005387 9.77 C3 CD40LG CFH CRP IL17A IL1B
3 renal/urinary system MP:0005367 9.23 C3 CD40LG CFH IL17A IL6 TLR2

Drugs & Therapeutics for Lyme Disease

Drugs for Lyme Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
2
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
5
Hydroxychloroquine Approved Phase 4 118-42-3 3652
6
Clarithromycin Approved Phase 4 81103-11-9 84029
7
Azithromycin Approved Phase 4 83905-01-5 55185 447043
8
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15
Cortisone Experimental Phase 4 53-06-5 222786
16 Antitubercular Agents Phase 4
17 Antibiotics, Antitubercular Phase 4
18 Antiviral Agents Phase 4
19 cefuroxime axetil Phase 4
20 penicillins Phase 4
21 Cytochrome P-450 CYP3A Inhibitors Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 valacyclovir Phase 4
24 Erythromycin Ethylsuccinate Phase 4
25 Erythromycin Estolate Phase 4
26 Erythromycin stearate Phase 4
27 Antiemetics Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Methylprednisolone Acetate Phase 4
30 Gastrointestinal Agents Phase 4
31 Hormone Antagonists Phase 4
32 Neuroprotective Agents Phase 4
33 Autonomic Agents Phase 4
34 glucocorticoids Phase 4
35 Protective Agents Phase 4
36 Antineoplastic Agents, Hormonal Phase 4
37 Hormones Phase 4
38
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
39
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
40
Acetaminophen Approved Phase 3 103-90-2 1983
41
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
42
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
43 Antiparasitic Agents Phase 2, Phase 3
44 Antiprotozoal Agents Phase 2, Phase 3
45 Antimalarials Phase 2, Phase 3
46 Antipyretics Phase 3
47 Antirheumatic Agents Phase 3
48 Analgesics, Non-Narcotic Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 3
50 Cyclooxygenase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment Completed NCT01635530 Phase 4 Doxycycline;Ceftriaxone
2 Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline. Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
3 Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome. Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
4 Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease Completed NCT01207739 Phase 4 Doxycycline;Clarithromycin and hydroxychloroquine;Placebo
5 A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy Completed NCT00510263 Phase 4 Prednisolone + placebo;Valaciclovir + placebo;Prednisolone + valaciclovir;Placebo + placebo
6 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
7 The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison Completed NCT00138801 Phase 3 Ceftriaxone;Doxycycline
10 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease Completed NCT00001101 Phase 3 ceftriaxone;doxycycline
11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease Completed NCT00000938 Phase 3 ceftriaxone;doxycycline
12 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
13 A Controlled Trial of a Primary and Secondary Program for Lyme Disease Completed NCT00000432 Phase 3
14 Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever Completed NCT00237016 Phase 2, Phase 3 doxycycline treatment
15 Symptomatic Management of Lyme Arthritis Recruiting NCT04038346 Phase 3 Naproxen;Acetaminophen
16 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial Enrolling by invitation NCT02553473 Phase 3 Doxycycline;Placebo
17 A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome Enrolling by invitation NCT04141969 Phase 2, Phase 3
18 Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Terminated NCT00958139 Phase 3
19 IV Ceftriaxone for Refractory Psychosis: a Controlled Trial Unknown status NCT00591318 Phase 1, Phase 2 ceftriaxone;Normal Saline
20 PET and MRI Imaging of Persistent Lyme Encephalopathy Completed NCT00037479 Phase 2 ceftriaxone
21 Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years Completed NCT01504347 Phase 1, Phase 2
22 A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers Completed NCT01243008 Phase 1, Phase 2 Application of SHB001
23 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Completed NCT01617083 Phase 2 Azithromycin;Placebo
24 Xenodiagnosis After Antibiotic Treatment for Lyme Disease - Phase II Study Recruiting NCT02446626 Phase 1, Phase 2
25 Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease Recruiting NCT03891667 Phase 1, Phase 2 Disulfiram 500 MG
26 Alternative Schedule Study For VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged 18 To 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study Active, not recruiting NCT03970733 Phase 2
27 Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study. Active, not recruiting NCT03769194 Phase 2
28 Using ReaLife+ to Treat Post-Lyme Disease Syndrome Active, not recruiting NCT04078841 Phase 1, Phase 2
29 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years Completed NCT03010228 Phase 1
30 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
31 Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count. Unknown status NCT00942006 doxycycline;ceftriaxone
32 Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans Unknown status NCT01163994 ceftriaxone;doxycycline
33 A School-Based Intervention to Reduce Lyme Disease Unknown status NCT00594997
34 Meditation and Stretching for Post Treatment Lyme Disease Syndrome Unknown status NCT02344537
35 Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome Unknown status NCT02687165 Milnacipran and D-cycloserine
36 Clinical Course, Serologic Response and Long-term Outcome in Elderly Patients With Early Lyme Borreliosis Completed NCT03371563 Antibiotics
37 Doxycycline in Therapy of Erythema Migrans - do the Accompanying Symptoms Influence the Outcome? Completed NCT01475708 Doxycycline
38 The Phenomenon of "Chronic Lyme"; an Observational Study Completed NCT01151150
39 Comparison of Two Culture Media for Cultivation of Borrelia Burgdorferi Sensu Lato Completed NCT02145754
40 Duration of Antibiotic Treatment of Erythema Migrans. A Randomized Clinical Trial. Completed NCT00910715 doxycycline;doxycycline;placebo
41 Inflammatory Responses in Borrelia Afzelii Culture Positive Patients With Early Disseminated or Early Localized Lyme Borreliosis Completed NCT03980015
42 Tick-Borne Encephalitis Virus and Lyme Borreliae Causing Coillness, Coinfection, or Just Coincidence. A Prospective Observational Study Completed NCT03958058 Anti-borrelial antibiotic therapy
43 Analysis of Erythema Migrans Lesions Completed NCT00132327
44 Searching for Persistence of Infection in Lyme Disease Completed NCT01143558 Early Phase 1
45 Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study Completed NCT01205464 Doxycycline;Placebo
46 Sofia 2 Lyme FIA Whole Blood Clinical Study Completed NCT03238274
47 Microbiologic Findings of Acute Facial Palsy in Children Completed NCT01537952
48 Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375 Completed NCT00034086 Lopinavir/Ritonavir;Lamivudine/Zidovudine;Tenofovir disoproxil fumarate;Lamivudine;Stavudine;Zidovudine;Didanosine
49 Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous Completed NCT02162992
50 A Single Group Trial to Determine the Complete Protection Time of an Insect Repellent Formulation Containing 30% Citriodiol® (Oil of Lemon Eucalyptus) Against Three Species of Ticks. Completed NCT03708120

Search NIH Clinical Center for Lyme Disease

Cochrane evidence based reviews: lyme disease

Genetic Tests for Lyme Disease

Anatomical Context for Lyme Disease

MalaCards organs/tissues related to Lyme Disease:

40
Testes, Heart, Skin, T Cells, Eye, Bone, Brain

Publications for Lyme Disease

Articles related to Lyme Disease:

(show top 50) (show all 10221)
# Title Authors PMID Year
1
Postoperative Lyme Arthritis in the Orthopaedic Patient. 61 42
31136727 2019
2
Lyme Disease. 61 42
31027665 2019
3
Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters. 61 42
31097026 2019
4
Functional characterization of Borrelia spielmanii outer surface proteins that interact with distinct members of the human factor H protein family and with plasminogen. 54 61
19858303 2010
5
Complement factor H binding by different Lyme disease and relapsing fever Borrelia in animals and human. 54 61
19604355 2009
6
Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov. 54 61
18706858 2009
7
Prospective study of serologic tests for lyme disease. 54 61
18532885 2008
8
Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC. 54 61
18417666 2008
9
Subacute transverse myelitis with Lyme profile dissociation. 54 61
19675732 2008
10
Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. 54 61
18248762 2008
11
Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi. 54 61
17160605 2006
12
Evidence that the BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. 54 61
16622245 2006
13
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. 54 61
16479520 2006
14
TLR2 expression in relation to IL-6 and IL-1beta and their natural regulators production by PMN and PBMC in patients with Lyme disease. 54 61
16864901 2006
15
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. 54 61
16081826 2005
16
Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. 54 61
16081885 2005
17
Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. 54 61
15939749 2005
18
[Effect of rhIL-15 on TLR2 expression and apoptosis of PMN from patients with Lyme disease]. 54 61
16130298 2005
19
Concentrations of macrophage inflammatory proteins MIP-1alpha and MIP-1beta and interleukin 8 (il-8) in lyme borreliosis. 54 61
15597225 2004
20
C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. 54 61
12853388 2003
21
Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. 54 61
12695997 2003
22
[Concentration of macrophage inflammatory proteins MIP-1 alpha and MIP-1 beta and interleukin 8 in erythema migrants]. 54 61
12362660 2002
23
[Lyme borreliosis--incidence of serum anti-myelin antibodies]. 54 61
11987581 2002
24
Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A. 54 61
11825956 2002
25
Recombinant flagellin A proteins from Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii in serodiagnosis of Lyme borreliosis. 54 61
11682523 2001
26
Recognition of multiple antibody epitopes throughout Borrelia burgdorferi p66, a candidate adhesin, in patients with early or late manifestations of Lyme disease. 54 61
11179382 2001
27
Downregulation of class II molecules on epidermal Langerhans cells in Lyme borreliosis. 54 61
11069457 2000
28
Reduced specificity of combined IgM and IgG enzyme immunoassay testing for lyme borreliosis. 54 61
10898148 2000
29
Evidence of Dbps (decorin binding proteins) among European strains of Borrelia burgdorferi sensu lato and in the immune response of LB patient sera. 54 61
10650211 2000
30
Utility of laboratory testing in autoimmune inner ear disease. 54 61
10569401 1999
31
Adherence of Borrelia burgdorferi. Identification of critical lysine residues in DbpA required for decorin binding. 54 61
10473582 1999
32
The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early lyme disease is the flaA gene product. 54 61
9986810 1999
33
The dominant epitope of Borrelia garinii outer surface protein C recognized by sera from patients with neuroborreliosis has a surface-exposed conserved structural motif. 54 61
9712750 1998
34
Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis. 54 61
9665957 1998
35
Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates. 54 61
9620365 1998
36
Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. 54 61
9542898 1998
37
Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies. 54 61
9455892 1998
38
Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis. 54 61
9350727 1997
39
Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. 54 61
9259573 1997
40
Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis. 54 61
9041433 1997
41
Polymerase chain reaction detection of Lyme disease: correlation with clinical manifestations and serologic responses. 54 61
8623775 1996
42
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. 54 61
8740122 1996
43
Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis. 54 61
8788993 1996
44
Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease. 54 61
8567889 1995
45
The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications. 54 61
7664493 1995
46
A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease. 54 61
7642278 1995
47
Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. 54 61
7768602 1995
48
Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition. 54 61
9158807 1995
49
Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. 54 61
8039891 1994
50
Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. 54 61
8077398 1994

Variations for Lyme Disease

Expression for Lyme Disease

Search GEO for disease gene expression data for Lyme Disease.

Pathways for Lyme Disease

Pathways related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF TLR9 TLR7 TLR6 TLR2 TLR1
2
Show member pathways
13.47 TNF TLR9 TLR7 TLR6 TLR2 TLR1
3
Show member pathways
13.26 TNF TLR9 TLR7 TLR6 TLR2 TLR1
4
Show member pathways
13.18 TNF TLR9 TLR7 TLR6 TLR2 TLR1
5
Show member pathways
12.89 TNF IL6 IL1B IL17A HSPD1 HLA-DRB1
6
Show member pathways
12.88 TNF TLR9 TLR7 TLR2 IL6 IL1B
7 12.86 TNF TLR9 TLR2 IL6 IL1B HLA-DRB1
8
Show member pathways
12.71 TNF TLR9 TLR7 TLR6 TLR2 TLR1
9
Show member pathways
12.68 TNF TLR9 TLR2 IL6 IL1B IL17A
10
Show member pathways
12.67 TNF TLR2 IL6 IL1B IL17A HLA-DRB1
11
Show member pathways
12.67 TNF TLR9 TLR7 TLR6 TLR2 TLR1
12
Show member pathways
12.46 TLR9 TLR7 TLR6 TLR2 TLR1
13 12.42 TNF TLR9 TLR7 TLR6 TLR2 TLR1
14
Show member pathways
12.39 TNF TLR2 IL6 IL1B IL17A
15
Show member pathways
12.35 TNF IL6 IL1B CRP
16
Show member pathways
12.35 TNF TLR2 IL1B HLA-DRB1 CD40LG C3
17
Show member pathways
12.35 TNF TLR9 TLR7 TLR6 TLR2 TLR1
18 12.32 TNF IL6 IL1B CLDN11
19
Show member pathways
12.26 TNF TLR2 IL6 IL1B
20
Show member pathways
12.25 TNF TLR9 IL6 IL1B
21 12.25 TNF IL6 IL1B HSPD1 C4A
22 12.22 TNF TLR9 TLR7 TLR6 TLR2 TLR1
23 12.2 CFHR2 CFHR1 CFH C4A C3
24 12.18 TLR6 TLR2 HLA-DRB1 C3
25
Show member pathways
12.16 CRP CFH C4A C3
26
Show member pathways
12.13 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
27
Show member pathways
12.12 CRP CFH C4A C3
28
Show member pathways
12.05 TNF TLR6 TLR2 TLR1 IL6 IL1B
29 12.04 TNF IL6 IL1B IL17A
30 11.99 TNF TLR2 IL6 IL1B
31
Show member pathways
11.98 TNF TLR9 TLR7 TLR6 TLR2 TLR1
32 11.97 TNF IL6 IL1B HLA-DRB1
33 11.96 TNF TLR2 IL6 IL1B IL17A HLA-DRB1
34 11.95 HLA-DRB1 CFH C4A C3
35 11.88 TLR9 TLR7 TLR6 TLR2 TLR1 C3
36 11.85 TNF IL6 IL1B C4A C3
37 11.83 TNF TLR9 TLR7 IL6 IL1B
38 11.81 TNF IL6 IL1B IL17A
39 11.8 TNF IL1B IL17A
40
Show member pathways
11.75 TNF IL6 IL1B CD40LG
41
Show member pathways
11.72 TNF TLR9 TLR7 TLR6 TLR2 TLR1
42 11.69 TNF IL6 IL1B
44 11.6 TNF TLR2 IL6 IL1B HSPD1 C3
45 11.58 TNF TLR9 TLR6 TLR2 TLR1 IL6
46 11.57 TNF IL6 IL1B
47 11.56 TNF TLR2 IL1B
48 11.53 TNF IL6 IL1B
49 11.5 TNF TLR9 TLR2 IL6 IL1B CD40LG
50 11.49 TNF TLR9 IL6 IL1B

GO Terms for Lyme Disease

Cellular components related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.85 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
2 cell surface GO:0009986 9.8 TNF TLR2 HSPD1 HLA-DRB1 CD40LG C3
3 membrane raft GO:0045121 9.73 TNF TLR6 TLR2 TLR1
4 extracellular region GO:0005576 9.73 TNF TLR9 IL6 IL1B IL17A CRP
5 phagocytic vesicle membrane GO:0030670 9.58 TLR6 TLR2 TLR1
6 blood microparticle GO:0072562 9.56 CFHR1 CFH C4A C3
7 early phagosome GO:0032009 9.46 TLR9 TLR7
8 extracellular space GO:0005615 9.36 TNF IL6 IL1B IL17A HSPD1 CRP
9 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 TLR9 TLR7 TLR6 TLR2 TLR1 IL6
2 immune system process GO:0002376 10.18 TLR9 TLR7 TLR6 TLR2 TLR1 HLA-DRB1
3 positive regulation of gene expression GO:0010628 10.14 TNF TLR9 TLR6 TLR2 IL6 IL1B
4 innate immune response GO:0045087 10.09 TLR9 TLR7 TLR6 TLR2 TLR1 CRP
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.02 TNF TLR9 TLR6 IL1B
6 regulation of complement activation GO:0030449 9.98 CFHR2 CFHR1 CFH C4A C3
7 defense response to Gram-positive bacterium GO:0050830 9.95 TNF TLR2 IL6 CRP
8 positive regulation of inflammatory response GO:0050729 9.95 TNF TLR9 TLR7 TLR2 IL1B
9 complement activation GO:0006956 9.93 CFHR1 CFH C4A C3
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR9 TLR7 TLR2 IL1B
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF TLR9 TLR6 TLR2 IL6 IL1B
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.9 TNF TLR9 TLR7
13 positive regulation of T cell proliferation GO:0042102 9.9 IL6 IL1B CD40LG
14 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B C3
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF TLR6 IL1B
16 positive regulation of interferon-gamma production GO:0032729 9.87 TNF IL1B HSPD1
17 positive regulation of interleukin-6 secretion GO:2000778 9.87 TNF TLR2 IL1B IL17A
18 microglial cell activation GO:0001774 9.86 TNF TLR7 TLR6 TLR2
19 positive regulation of JUN kinase activity GO:0043507 9.85 TNF TLR9 TLR6
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 TNF TLR2 IL1B
21 toll-like receptor signaling pathway GO:0002224 9.85 TLR9 TLR7 TLR6 TLR2 TLR1
22 positive regulation of interleukin-12 production GO:0032735 9.84 TLR9 TLR2 HSPD1 CD40LG
23 positive regulation of vascular endothelial growth factor production GO:0010575 9.83 IL6 IL1B C3
24 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
25 positive regulation of interleukin-10 production GO:0032733 9.83 TLR9 TLR2 HSPD1 CD40LG
26 positive regulation of glial cell proliferation GO:0060252 9.8 TNF IL6 IL1B
27 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.8 TNF TLR9 TLR7
28 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.8 TNF TLR6 TLR1 IL1B
29 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR9 TLR7 TLR2 IL1B
30 positive regulation of neuroinflammatory response GO:0150078 9.79 TNF IL6 IL1B
31 I-kappaB phosphorylation GO:0007252 9.79 TLR9 TLR7 TLR2
32 cell activation GO:0001775 9.78 TLR6 TLR2 TLR1
33 regulation of cytokine secretion GO:0050707 9.78 TLR9 TLR6 TLR2 TLR1
34 negative regulation of lipid storage GO:0010888 9.77 TNF IL6 CRP
35 positive regulation of chemokine biosynthetic process GO:0045080 9.73 TNF IL1B
36 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 TLR9 IL1B
37 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.73 TLR9 TLR7 TLR6 TLR2 TLR1 HSPD1
38 immune response GO:0006955 9.73 TNF TLR9 TLR7 TLR6 TLR2 TLR1
39 positive regulation of cytolysis GO:0045919 9.72 CFHR2 CFHR1
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.72 TLR9 TLR7
41 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
42 positive regulation of chemokine production GO:0032722 9.72 TNF TLR9 TLR7 TLR2 IL6
43 positive regulation of apoptotic cell clearance GO:2000427 9.71 C4A C3
44 cellular response to diacyl bacterial lipopeptide GO:0071726 9.71 TLR6 TLR2
45 regulation of immunoglobulin secretion GO:0051023 9.71 TNF CD40LG
46 positive regulation of interleukin-18 production GO:0032741 9.71 TLR9 TLR2
47 tumor necrosis factor production GO:0032640 9.7 TLR9 TLR2
48 positive regulation of fever generation GO:0031622 9.7 TNF IL1B
49 positive regulation of interleukin-6 production GO:0032755 9.7 TNF TLR9 TLR7 TLR2 IL6 IL1B
50 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.69 TLR9 TLR7

Molecular functions related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 YBX3 TNF TLR9 TLR7 TLR6 TLR2
2 transmembrane signaling receptor activity GO:0004888 9.67 TLR9 TLR7 TLR6 TLR1
3 cytokine activity GO:0005125 9.55 TNF IL6 IL1B IL17A CD40LG
4 siRNA binding GO:0035197 9.43 TLR9 TLR7
5 complement component C1q binding GO:0001849 9.4 CRP C4A
6 Toll-like receptor 2 binding GO:0035663 9.32 TLR6 TLR1
7 signaling pattern recognition receptor activity GO:0008329 9.13 TLR9 TLR7 TLR2
8 lipopeptide binding GO:0071723 8.8 TLR6 TLR2 TLR1

Sources for Lyme Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....